Altura Medical Announces G. Ray Martin Named President & CEO

The Associated Press

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Aug 14, 2012--Altura Medical, Inc., an early stage medical device manufacturer, announced the appointment of G. Ray Martin, Ph.D. as Altura's President and Chief Executive Officer and a member of the Board of Directors. Dr. Martin brings 20 years of relevant industry experience to his new role having previously served as President and CEO of NovoStent. Prior to that, he was a Vice President of Business Development at Boston Scientific, as well as Trivascular, which was acquired by Boston Scientific. Before joining Trivascular, Dr. Martin held executive positions at C.R. Bard and W.L. Gore, where he led the development of various stent graft devices.

Dr. Martin is a Summa Cum Laude graduate of West Virginia University, where he received a B.S. in Chemical Engineering, and he holds a Ph.D. in Chemical Engineering and Bioengineering from Carnegie Mellon University.

"We are excited about G. Ray joining the Altura team. His experience and leadership will be instrumental in guiding the company through the development and commercialization of Altura's unique endograft technology," said George Wallace, founder, former acting CEO and a member of the Board of Directors. "I am looking forward to leveraging Altura's early success to build a company that will provide physicians with a new concept for treating their AAA patients. I believe that Altura's novel approach will not only significantly benefit routine patients, but will offer an easy-to-use solution in patients with more complex anatomy," said Dr. Martin.

About Altura Medical, Inc. Altura Medical, Inc., a privately held early stage medical device company with current headquarters in San Clemente, CA, was founded in 2008. Major venture investors include SV Life Sciences, New Leaf Venture Partners, and Advanced Technology Ventures. Altura Medical is focused on devices and methods for the treatment of aneurysms in the arterial vascular system. With a FIM clinical trial started in June 2011, Altura Medical will expand clinical evaluations to support regulatory approval and commercialization. This effort will be supported with operations being established in the San Francisco Bay Area.

Altura Endograft Device The Altura Endograft is the first and only independently aligned system that is designed to provide a solution to some of the major issues associated with conventional AAA repair procedures. The unique design allows physicians to have more precise control over graft placement through an ultra-low profile device.

About AAA It is estimated that approximately 4.5 million people are living with an abdominal aortic aneurysm in the developed world (1.5 million in the U.S.) and each

year 600,000 new cases are diagnosed (250,000 in the U.S.). Patients typically have no symptoms and when they are diagnosed, they often undergo complex surgical repair. Endovascular therapy provides a minimally invasive alternative, with reduced recovery times and improved survival rates.

CONTACT: Altura Medical, Inc.

Leslie Hamer, 949-273-5050 Facsimile: 949-273-5054 lhamer@alturainc.com
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES RADIOLOGY OTHER HEALTH SOURCE: Altura Medical, Inc. Copyright Business Wire 2012 PUB: 08/14/2012 01:34 PM/DISC: 08/14/2012 01:34 PM
http://www.businesswire.com/news/home/20120814006348/

Source URL (retrieved on *07/26/2014 - 5:24am*):
http://www.mdtmag.com/news/2012/08/altura-medical-announces-g-ray-martin-named-president-ceo